CALGARY, Nov. 29 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) is pleased to announce today that it has filed
additional new patent protection based on novel findings derived from
its recently completed ASSERT Phase 2 clinical trial. A new patent
application has been filed for novel dosing combinations of RVX-208 and
leading statin therapeutics. The patent was filed based on the results
demonstrated in the ASSERT trial. Resverlogix' findings in a post-hoc
analysis of ASSERT data revealed that RVX-208 in certain doses along
with leading statin drugs markedly improved not only ApoA-I production,
HDL and large HDL particles, but also important aspects of LDL and ApoB
particles. All of these positive changes took place in patients on the
best standard of care currently available.
"The bonus finding of ApoB and LDL lowering while on statins and not in
placebo's was a surprise finding and is useful in selecting the best
statin co-medications going forward for maximum treatment effect. The
effects seem most efficacious in the leading stains, being Pfizer's
Lipitor and AstraZeneca's Crestor. Resverlogix will further delineate
this positive synergistic effect from a mechanistic point of view,"
stated Dr. Jan Johansson, Senior Vice President of Medical Affairs of
Resverlogix. "To have these additional findings of unexpected enhanced
statin performance, in combination with RVX-208, offers us an added
approach to providing an array of new therapies to reduce
atherosclerosis and coronary vascular disease," Dr. Johansson added.
"ASSERT, as it was designed to do, taught us several key findings,"
stated Kenneth Lebioda, Senior Vice President Business & Corporate
Development of Resverlogix. "We now understand with greater clarity
that RVX-208 works better in high risk patients with low HDL and that
certain doses have far greater effect in promoting markers of reverse
cholesterol transport (RCT). After careful analysis of all the data we
also found that when RVX-208 is used with certain statins we see
significant reductions in liver signals such as ALTs while still
maintaining very good efficacy. These key findings have helped us
immensely in designing a more powerful, accurate and targeted ASSURE
Phase 2b trial. In terms of business development this new patent
filing greatly expands the scope of our commercial program," Lebioda
added.
Resverlogix to Host Webcast Today
Resverlogix Corp. will host a live teleconference and webcast on Monday,
November 29, 2010 at 11:00 am Mountain time. The purpose of the
teleconference is to provide a market update from management. The
dial-in numbers for this event are toll free 1-800-319-4610 and
international 1-604-638-5340. A link for this webcast will be posted
onto the homepage of Resverlogix's website and can be accessed from the
following address
https://services.choruscall.com/links/resverlogix101129.html.
The webcast will be available on the Resverlogix website for replay for
a period of 45 days after the event.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet needs. The NexVas™ PR program is the Company's
primary focus which is to develop novel small molecules that enhance
ApoA-I. These vital therapies address the grievous burden of
atherosclerosis and other important diseases such as Acute Coronary
Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and
other vascular disorders. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements
are subject to a number of risks, uncertainties and assumptions. Actual
results and events may vary significantly. The TSX Exchange does not
accept responsibility for the adequacy or accuracy of this news
release.